Inhibiting TGFß Receptors Reduces Chronic Inflammation and Plaque in Atherosclerosis

Atherosclerosis involves the development of lipid deposits, called plaques, in blood vessel walls. Plaques narrow and weaken those vessels, ultimately producing the inevitable structural failure of a stroke or heart attack. Perhaps a sixth of humanity dies because of atherosclerosis, but means to treat the condition are so far only capable of somewhat slowing it down, with little reversal of existing plaque. Most approaches, such as statin drugs, focus on reducing the level of lipids in circulation in the bloodstream. Why does a reduction of blood lipids work to slow atherosclerosis? Atherosclerosis is a condition of dysfunctional macrophages. The immune cells called macrophages are responsible for clearing lipid deposits from blood vessel walls. Where cells become disturbed by the presence of lipids, they secrete inflammatory signals calling

From http://besthealthnews.com/2019/09/inhibiting-tgfs-receptors-reduces-chronic-inflammation-and-plaque-in-atherosclerosis/?utm_source=rss&utm_medium=rss&utm_campaign=inhibiting-tgfs-receptors-reduces-chronic-inflammation-and-plaque-in-atherosclerosis

from
https://healthnews010.wordpress.com/2019/09/04/inhibiting-tgfs-receptors-reduces-chronic-inflammation-and-plaque-in-atherosclerosis/

From https://jamesjohnson10.blogspot.com/2019/09/inhibiting-tgf-receptors-reduces.html

from
https://jamesjohnson10.wordpress.com/2019/09/04/inhibiting-tgfs-receptors-reduces-chronic-inflammation-and-plaque-in-atherosclerosis/